open access

Vol 6, No 2 (2017)
Review articles (submitted)
Published online: 2017-08-03
Get Citation

Alprostadil in cream — a new option of treating erectile dysfunctions in diabetic patients

Marcin Życzkowski, Katarzyna Nabrdalik, Hanna Kwiendacz, Diana Nabrdalik-Leśniak, Janusz Gumprecht
DOI: 10.5603/DK.2017.0012
·
Clinical Diabetology 2017;6(2):70-75.

open access

Vol 6, No 2 (2017)
Review articles (submitted)
Published online: 2017-08-03

Abstract

Diabetes mellitus is a risk factor for many urological complications, with the most frequent one in men, erectile dysfunction, occurring in patients with diabetes three times more often than in men with normal glucose tolerance. Diabetes contributes to erectile dysfunction through endothelial dysfunction, neuropathy, structural and functional dysfunction of cavernous bodies’ smooth muscles and hormonal disorders. Alprostadil is a synthetic form of Prostaglandin E1, which directly affects arterial smooth muscles and causes vasodilatation. Besides being administrated deeply into the urethra and via injections into cavernous bodies, it might be used as a cream, which is rapidly and almost entirely absorbed into corpus spongiosum and cavernous bodies. It might be used as a first-line treatment for patients who have contraindications for PDE5 inhibitors or prefer topical application of the drug and as a second-line treatment in case of intolerance or no response to PDE5i, also for more complicated clinical cases, often occurring in diabetes. Alprostadil is administrated into the external urethral meatus 5–30 minutes before sexual intercourse; a complete erection appears in 10–12 minutes and lasts 1–2 hours. Due to lack of systemic effects, alprostadil in cream is safe and well tolerated, moreover, it does not interact with intake of food and alcohol. The advanced and effective therapy of erectile dysfunctions, which is alprostadil, helps to improve the quality of life in patients with diabetes.

Abstract

Diabetes mellitus is a risk factor for many urological complications, with the most frequent one in men, erectile dysfunction, occurring in patients with diabetes three times more often than in men with normal glucose tolerance. Diabetes contributes to erectile dysfunction through endothelial dysfunction, neuropathy, structural and functional dysfunction of cavernous bodies’ smooth muscles and hormonal disorders. Alprostadil is a synthetic form of Prostaglandin E1, which directly affects arterial smooth muscles and causes vasodilatation. Besides being administrated deeply into the urethra and via injections into cavernous bodies, it might be used as a cream, which is rapidly and almost entirely absorbed into corpus spongiosum and cavernous bodies. It might be used as a first-line treatment for patients who have contraindications for PDE5 inhibitors or prefer topical application of the drug and as a second-line treatment in case of intolerance or no response to PDE5i, also for more complicated clinical cases, often occurring in diabetes. Alprostadil is administrated into the external urethral meatus 5–30 minutes before sexual intercourse; a complete erection appears in 10–12 minutes and lasts 1–2 hours. Due to lack of systemic effects, alprostadil in cream is safe and well tolerated, moreover, it does not interact with intake of food and alcohol. The advanced and effective therapy of erectile dysfunctions, which is alprostadil, helps to improve the quality of life in patients with diabetes.

Get Citation

Keywords

diabetes mellitus, erectile dysfunction, alprostadil

About this article
Title

Alprostadil in cream — a new option of treating erectile dysfunctions in diabetic patients

Journal

Clinical Diabetology

Issue

Vol 6, No 2 (2017)

Pages

70-75

Published online

2017-08-03

DOI

10.5603/DK.2017.0012

Bibliographic record

Clinical Diabetology 2017;6(2):70-75.

Keywords

diabetes mellitus
erectile dysfunction
alprostadil

Authors

Marcin Życzkowski
Katarzyna Nabrdalik
Hanna Kwiendacz
Diana Nabrdalik-Leśniak
Janusz Gumprecht

References (41)
  1. Sayyid RK, Fleshner NE. Diabetes Mellitus Type 2: A Driving Force for Urological Complications. Trends Endocrinol Metab. 2016; 27(5): 249–261.
  2. Rew KT, Heidelbaugh JJ. Erectile Dysfunction. Am Fam Physician. 2016; 94(10): 820–827.
  3. Isidro ML. Sexual dysfunction in men with type 2 diabetes. Postgrad Med J. 2012; 88(1037): 152–159.
  4. Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med. 2009; 6(5): 1232–1247.
  5. Hatzimouratidis K, Hatzichristou D. How to treat erectile dysfunction in men with diabetes: from pathophysiology to treatment. Curr Diab Rep. 2014; 14(11): 545.
  6. Price D, Hackett G. Management of erectile dysfunction in diabetes: an update for 2008. Curr Diab Rep. 2008; 8(6): 437–443.
  7. Mazzilli R, Elia J, Delfino M, et al. Prevalence of Diabetes Mellitus (DM) in a population of men affected by Erectile Dysfunction (ED). Clin Ter. 2015; 166(5): e317–e320.
  8. Basu A, Ryder REJ. New treatment options for erectile dysfunction in patients with diabetes mellitus. Drugs. 2004; 64(23): 2667–2688.
  9. Binmoammar TA, Hassounah S, Alsaad S, et al. The impact of poor glycaemic control on the prevalence of erectile dysfunction in men with type 2 diabetes mellitus: a systematic review. JRSM Open. 2016; 7(3): 2054270415622602.
  10. Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation. European Urology. 2010; 57(5): 804–814.
  11. Phé V, Rouprêt M. Erectile dysfunction and diabetes: a review of the current evidence-based medicine and a synthesis of the main available therapies. Diabetes Metab. 2012; 38(1): 1–13.
  12. Gołąbek T, et al. Zalecenia zespołu ekspertów dotyczące leczenia alprostadylem w kremie chorych z zaburzeniami wzwodu. Przegl Urol. 2016; 5: 34–39.
  13. Corona G, Giorda CB, Cucinotta D, et al. Gruppo di studio SUBITO-DE. Sexual dysfunction at the onset of type 2 diabetes: the interplay of depression, hormonal and cardiovascular factors. J Sex Med. 2014; 11(8): 2065–2073.
  14. Porst H, Burnett A, Brock G, et al. ISSM Standards Committee for Sexual Medicine. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013; 10(1): 130–171.
  15. Moisidis K, Kalinderis N, Hatzimouratidis K, et al. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs. 2005; 65(12): 1621–1650.
  16. Adaikan PG, Kottegoda SR, Ratnam SSA. possible role for prostaglandin E1 in human penile erection. Proceedings of the Second World Meeting on Impotence, Prague, Czechoslovakia. 1986; Abstract. ; 2: 6.
  17. Palmer LS, Valcic M, Melman A, et al. Characterization of cyclic AMP accumulation in cultured human corpus cavernosum smooth muscle cells. J Urol. 1994; 152(4): 1308–1314.
  18. Traish AM, Moreland RB, Gallant C, et al. G-protein-coupled receptor agonists augment adenylyl cyclase activity induced by forskolin in human corpus cavernosum smooth muscle cells. Recept Signal Transduct. 1997; 7(2): 121–132.
  19. Lewis RW, Fugl-Meyer KS, Corona G, et al. Epidemiology/risk factors of sexual dysfunction. J Sex Med. 2004; 1(1): 35–39.
  20. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007; 120(2): 151–157.
  21. Buvat J, Maggi M, Gooren L, et al. Endocrine aspects of male sexual dysfunctions. J Sex Med. 2010; 7(4 Pt 2): 1627–1656.
  22. McVary KT, et al. Sexual Dysfunction, in Harrison's Principles of Internal Medicine, Longo DL, , Editors. 2012, McGraw Hill. : 374–379.
  23. Gandhi J, Dagur G, Warren K, et al. The Role of Sexual Dysfunction and Infertility on Reproductive Health in Diabetics: Pathogenesis, Evaluation, and Management. Curr Diabetes Rev. 2016 [Epub ahead of print].
  24. Caretta N, de Kreutzenberg SV, Valente U, et al. Hypovitaminosis D is associated with erectile dysfunction in type 2 diabetes. Endocrine. 2016; 53(3): 831–838.
  25. Furukawa S, Sakai T, Niiya T, et al. Self-reported sitting time and prevalence of erectile dysfunction in Japanese patients with type 2 diabetes mellitus: The Dogo Study. J Diabetes Complications. ; 2017;31(1):53-57..
  26. Matsui H, Musicki B, Sopko NA, et al. Early-stage Type 2 Diabetes Mellitus Impairs Erectile Function and Neurite Outgrowth From the Major Pelvic Ganglion and Downregulates the Gene Expression of Neurotrophic Factors. Urology. 2017; 99: 287.e1–287.e7.
  27. Hurdag C, Ozkara H, Citci S, et al. The effects of alpha-lipoic acid on nitric oxide synthetase dispersion in penile function in streptozotocin-induced diabetic rats. Int J Tissue React. 2005; 27(3): 145–150.
  28. Zhang L, Zhang HY, Huang FC, et al. Study on the clinical value of alprostadil combined with α-lipoic acid in treatment of type 2 diabetes mellitus patients with erectile dysfunction. Eur Rev Med Pharmacol Sci. 2016; 20(18): 3930–3933.
  29. Tjandra BS, Janknegt RA. Neurogenic impotence and lower urinary tract symptoms due to vitamin B1 deficiency in chronic alcoholism. J Urol. 1997; 157(3): 954–955.
  30. Becher E. Topical alprostadil cream for the treatment of erectile dysfunction. Expert Opin Pharmacother. 2004; 5(3): 623–632.
  31. Ishii N, Watanabe H, Irisawa C, et al. [Studies on male sexual impotence. Report 18. Therapeutic trial with prostaglandin E1 for organic impotence]. Nihon Hinyokika Gakkai Zasshi. 1986; 77(6): 954–962.
  32. Beihn RM. Gamma scintigraphy measurement of the retention and migration of an erectile dysfunction topical formulation applied to the tip of the human male penis. Data on file at NexMed (USA), Inc.; Protocol No. NEXSCIN 2001-001; US IND No 53. ; 953: 2002.
  33. Becher E, Borghi M, Momesso A. Montes De Oca L. Penile hemodynamic finding with a new topical formulation of alprostadil. J Urol 1998; 159 (Suppl2. ; 239(Abstract 915).
  34. Yeager J, Beihn RM. Retention and migration of alprostadil cream applied topically to the glans meatus for erectile dysfunction. Int J Impot Res. 2005; 17(1): 91–95.
  35. http://pub.rejestrymedyczne.csioz.gov.pl/ProduktSzczegoly.aspx?id=35177.
  36. Steidle C, Padma-Nathan H, Salem S, et al. Topical alprostadil cream for the treatment of erectile dysfunction: a combined analysis of the phase II program. Urology. 2002; 60(6): 1077–1082.
  37. Padma-Nathan H, Steidle C, Salem S, et al. The efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two phase 2 studies in mild-to-moderate and severe ED. Int J Impot Res. 2003; 15(1): 10–17.
  38. Padma-Nathan H, Yeager JL. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology. 2006; 68(2): 386–391.
  39. Rooney M, Pfister W, Mahoney M, et al. Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction. J Sex Med. 2009; 6(2): 520–534.
  40. Mulhall J, Porst H, Goldstein I, et al. Comparison of Vitaros efficacy and safety with short-term and long-term Use. ESSM-ISSM Berlin. ; 2013: Poster.
  41. Moncada I, Cuzin B. Clinical efficacy and safety of Vitaros©/Virirec© (Alprostadil cream) for the treatment of erectile dysfunction. Urologia. 2015; 82(2): 84–92.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl